184 related articles for article (PubMed ID: 34362793)
1. Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys.
Lopes JE; Sun L; Flick HL; Murphy EA; Losey HC
J Pharmacol Exp Ther; 2021 Nov; 379(2):203-210. PubMed ID: 34362793
[TBL] [Abstract][Full Text] [Related]
2. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
3. TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
Rosen DB; Kvarnhammar AM; Laufer B; Knappe T; Karlsson JJ; Hong E; Lee YC; Thakar D; Zúñiga LA; Bang K; Sabharwal SS; Uppal K; Olling JD; Kjaergaard K; Kurpiers T; Schnabel M; Reich D; Glock P; Zettler J; Krusch M; Bernhard A; Heinig S; Konjik V; Wegge T; Hehn Y; Killian S; Viet L; Runz J; Faltinger F; Tabrizi M; Abel KL; Breinholt VM; Singel SM; Sprogøe K; Punnonen J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817480
[TBL] [Abstract][Full Text] [Related]
4. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
[TBL] [Abstract][Full Text] [Related]
5. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
6. Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer.
Pan Y; Hao Y; Han H; Chen T; Ding H; Labbe KE; Shum E; Guidry K; Hu H; Sherman F; Geng K; Stephens J; Chafitz A; Tang S; Huang HY; Peng C; Almonte C; Lopes JE; Losey HC; Winquist RJ; Velcheti V; Zhang H; Wong KK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36472839
[TBL] [Abstract][Full Text] [Related]
7. ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Herzog TJ; Hays JL; Barlin JN; Buscema J; Cloven NG; Kong LR; Tyagi NK; Lanneau GS; Long BJ; Marsh RL; Seward SM; Starks DC; Welch S; Moore KN; Konstantinopoulos PA; Gilbert L; Monk BJ; O'Malley DM; Chen X; Dalal R; Coleman RL; Sehouli J
Future Oncol; 2023 Jul; 19(23):1577-1591. PubMed ID: 37334673
[TBL] [Abstract][Full Text] [Related]
8. Complex PK-PD of an engineered IL-15/IL-15Rα-Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics.
Lu D; Yadav R; Holder P; Chiang E; Sanjabi S; Poon V; Bernett M; Varma R; Liu K; Leung I; Bogaert L; Desjarlais J; Shivva V; Hosseini I; Ramanujan S
Eur J Pharm Sci; 2023 Jul; 186():106450. PubMed ID: 37084985
[TBL] [Abstract][Full Text] [Related]
9. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
[TBL] [Abstract][Full Text] [Related]
10. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
Charych D; Khalili S; Dixit V; Kirk P; Chang T; Langowski J; Rubas W; Doberstein SK; Eldon M; Hoch U; Zalevsky J
PLoS One; 2017; 12(7):e0179431. PubMed ID: 28678791
[TBL] [Abstract][Full Text] [Related]
11. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
Nnane IP; Han C; Jiao Q; Tam SH; Davis HM; Xu Z
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):13-21. PubMed ID: 28132416
[TBL] [Abstract][Full Text] [Related]
12. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.
Krieg C; Létourneau S; Pantaleo G; Boyman O
Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11906-11. PubMed ID: 20547866
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics, and toxicity of a PD-1-targeted IL-15 in cynomolgus monkeys.
Ji C; Kuang B; Buetow BS; Vitsky A; Xu Y; Huang TH; Chaparro-Riggers J; Kraynov E; Matsumoto D
PLoS One; 2024; 19(2):e0298240. PubMed ID: 38315680
[TBL] [Abstract][Full Text] [Related]
14. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
15. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2.
Casetti R; Perretta G; Taglioni A; Mattei M; Colizzi V; Dieli F; D'Offizi G; Malkovsky M; Poccia F
J Immunol; 2005 Aug; 175(3):1593-8. PubMed ID: 16034098
[TBL] [Abstract][Full Text] [Related]
17. Effects of an agonist interleukin-2/Fc fusion protein, a mutant antagonist interleukin-15/Fc fusion protein, and sirolimus on cardiac allograft survival in non-human primates.
Millington T; Koulmanda M; Ng C; Boskovic S; Nadazdin OM; Benichou G; Zheng XX; Strom TB; Madsen JC
J Heart Lung Transplant; 2012 Apr; 31(4):427-35. PubMed ID: 22366291
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.
Yamada Y; Aoyama A; Tocco G; Boskovic S; Nadazdin O; Alessandrini A; Madsen JC; Cosimi AB; Benichou G; Kawai T
J Immunol; 2012 Jun; 188(12):6063-70. PubMed ID: 22586034
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells.
Sereti I; Martinez-Wilson H; Metcalf JA; Baseler MW; Hallahan CW; Hahn B; Hengel RL; Davey RT; Kovacs JA; Lane HC
Blood; 2002 Sep; 100(6):2159-67. PubMed ID: 12200381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]